NO2825156T3 - - Google Patents
Info
- Publication number
- NO2825156T3 NO2825156T3 NO13710293A NO13710293A NO2825156T3 NO 2825156 T3 NO2825156 T3 NO 2825156T3 NO 13710293 A NO13710293 A NO 13710293A NO 13710293 A NO13710293 A NO 13710293A NO 2825156 T3 NO2825156 T3 NO 2825156T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12001803 | 2012-03-16 | ||
| PCT/EP2013/000698 WO2013135359A1 (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
| EP13710293.5A EP2825156B1 (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2825156T3 true NO2825156T3 (sr) | 2017-12-23 |
Family
ID=47901004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO13710293A NO2825156T3 (sr) | 2012-03-16 | 2013-03-11 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9878044B2 (sr) |
| EP (1) | EP2825156B1 (sr) |
| JP (2) | JP6527331B2 (sr) |
| KR (2) | KR102208586B1 (sr) |
| CN (1) | CN104168888A (sr) |
| AU (2) | AU2013231638B2 (sr) |
| BR (1) | BR112014022451B1 (sr) |
| CA (1) | CA2867169C (sr) |
| DK (1) | DK2825156T3 (sr) |
| ES (1) | ES2644778T3 (sr) |
| HK (1) | HK1198924A1 (sr) |
| IL (1) | IL234550A (sr) |
| MX (1) | MX354811B (sr) |
| NO (1) | NO2825156T3 (sr) |
| NZ (1) | NZ631034A (sr) |
| PT (1) | PT2825156T (sr) |
| RU (1) | RU2654210C2 (sr) |
| SG (2) | SG11201405552VA (sr) |
| TW (1) | TWI586370B (sr) |
| WO (1) | WO2013135359A1 (sr) |
| ZA (1) | ZA201407490B (sr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2347774B1 (en) | 2005-12-13 | 2017-07-26 | The President and Fellows of Harvard College | Scaffolds for cell transplantation |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP6104806B2 (ja) | 2010-10-06 | 2017-03-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2838515B1 (en) | 2012-04-16 | 2019-11-20 | President and Fellows of Harvard College | Mesoporous silica compositions for modulating immune responses |
| LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EP3981437A1 (en) | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
| EP3250250A4 (en) | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY |
| JP7094533B2 (ja) | 2015-04-10 | 2022-07-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫細胞捕捉デバイスおよびその製造および使用方法 |
| CN108350605A (zh) * | 2015-09-04 | 2018-07-31 | 台湾浩鼎生技股份有限公司 | 聚糖阵列以及使用方法 |
| EP3736261B1 (en) | 2015-09-17 | 2023-10-11 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN105505382B (zh) * | 2015-12-04 | 2017-06-27 | 安徽师范大学 | 一种铜纳米簇溶液的制备方法及应用 |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| JP7138864B2 (ja) | 2016-02-06 | 2022-09-20 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫を再構成するための造血ニッチの再現 |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| SG11201809024UA (en) | 2016-04-22 | 2018-11-29 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| WO2017201340A2 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
| CN109789092A (zh) * | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| CN110072545A (zh) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | 免疫原性/治疗性聚糖组合物及其用途 |
| KR102528998B1 (ko) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | 인간 항체, 제약 조성물 및 방법 |
| US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
| CN110312799A (zh) * | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
| WO2018038549A1 (ko) * | 2016-08-24 | 2018-03-01 | 울산대학교 산학협력단 | Dtbp를 이용한 미생물 농축 또는 핵산 추출 방법 |
| KR102026683B1 (ko) | 2016-08-24 | 2019-09-30 | 울산대학교 산학협력단 | Dtbp를 이용한 미생물 농축 또는 핵산 추출 방법 |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| TWI822055B (zh) | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| DE17829597T1 (de) * | 2016-11-30 | 2019-12-05 | Noxxon Pharma Ag | Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz |
| ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| ES2940259T3 (es) | 2017-03-15 | 2023-05-04 | Modernatx Inc | Compuesto y composiciones para la administración intracelular de agentes terapéuticos |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| AU2017438994A1 (en) * | 2017-11-09 | 2020-05-28 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof |
| TW202035444A (zh) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
| CA3133136A1 (en) | 2019-03-13 | 2020-09-17 | Merck Patent Gmbh | Process for the preparation of lipidated proteinaceous structures |
| JP2022548304A (ja) | 2019-09-19 | 2022-11-17 | モデルナティエックス インコーポレイテッド | 治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2967069D1 (en) | 1978-01-16 | 1984-08-02 | Univ Boston | Effecting cellular uptake of molecules |
| US4144034A (en) * | 1978-03-27 | 1979-03-13 | Texaco Inc. | Polyether-maleic anhydride reaction product containing motor fuel composition |
| ATE31560T1 (de) | 1983-11-10 | 1988-01-15 | Hoesch Ag | Verfahren und vorrichtung zum elektrolytischen abscheiden von metallen. |
| US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| IT1254135B (it) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica. |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| EP0975370B9 (en) | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| CA2370690A1 (en) * | 1999-04-20 | 2000-10-26 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| WO2001022995A1 (en) | 1999-09-30 | 2001-04-05 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
| JP4678967B2 (ja) * | 2001-03-08 | 2011-04-27 | 本田技研工業株式会社 | ゲル化性有機化合物及びそれを用いるゲル |
| GB0106041D0 (en) * | 2001-03-12 | 2001-05-02 | Cancer Res Ventures Ltd | Lipids and liposomes |
| EP2415486B1 (en) | 2001-05-18 | 2017-02-22 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| JP5093547B2 (ja) * | 2001-08-24 | 2012-12-12 | 日本ケミカルリサーチ株式会社 | 両イオン性脂質およびその用途 |
| WO2003022910A1 (en) | 2001-09-08 | 2003-03-20 | Access Pharmaceuticals, Inc. | Synthesis and uses of polymer gel nanoparticle networks |
| EP1308167A1 (de) | 2001-11-06 | 2003-05-07 | Pickl, Winfried, Ao. Univ. Prof. Dr. | Antigenpräsentierende Vesikel |
| JP4331927B2 (ja) * | 2002-08-29 | 2009-09-16 | 協立化学産業株式会社 | 無機ナノ粒子−有機化合物複合体およびそれの一次元配列集積構造体 |
| AU2004248138B2 (en) * | 2003-05-29 | 2009-09-03 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
| US20070292354A1 (en) | 2004-09-23 | 2007-12-20 | Guerbet | Contrast Agents Encapsulating Systems for Cest Imaging |
| US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
| US20090285881A1 (en) * | 2008-04-16 | 2009-11-19 | Abbott Laboratories | Cationic lipids and uses thereof |
| US20100104629A1 (en) | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
| WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| RU2409587C2 (ru) * | 2009-03-04 | 2011-01-20 | Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" | 1-гексадецил-5-(1-пиренбутил)-n-(l-орнитил)-l-глутамат бисхлорид |
| PT2611421T (pt) | 2010-09-02 | 2018-11-22 | Scripps Research Inst | Administração de fármaco dirigida a tumor à base de nanopartículas |
| US20120294924A1 (en) * | 2011-04-29 | 2012-11-22 | Thomas Tice | Peptide-Lipid Conjugates And Uses Thereof |
| MX359736B (es) * | 2012-03-16 | 2018-10-09 | Merck Patent Gmbh | Lipidos de aminoacidos. |
-
2013
- 2013-03-11 ES ES13710293.5T patent/ES2644778T3/es active Active
- 2013-03-11 NZ NZ631034A patent/NZ631034A/en unknown
- 2013-03-11 RU RU2014141545A patent/RU2654210C2/ru active
- 2013-03-11 KR KR1020147028906A patent/KR102208586B1/ko active IP Right Grant
- 2013-03-11 JP JP2014561310A patent/JP6527331B2/ja active Active
- 2013-03-11 EP EP13710293.5A patent/EP2825156B1/en active Active
- 2013-03-11 WO PCT/EP2013/000698 patent/WO2013135359A1/en active Application Filing
- 2013-03-11 KR KR1020207008113A patent/KR20200036033A/ko not_active Application Discontinuation
- 2013-03-11 PT PT137102935T patent/PT2825156T/pt unknown
- 2013-03-11 DK DK13710293.5T patent/DK2825156T3/en active
- 2013-03-11 SG SG11201405552VA patent/SG11201405552VA/en unknown
- 2013-03-11 BR BR112014022451-0A patent/BR112014022451B1/pt active IP Right Grant
- 2013-03-11 SG SG10201610401XA patent/SG10201610401XA/en unknown
- 2013-03-11 AU AU2013231638A patent/AU2013231638B2/en active Active
- 2013-03-11 CA CA2867169A patent/CA2867169C/en active Active
- 2013-03-11 US US14/384,702 patent/US9878044B2/en active Active
- 2013-03-11 CN CN201380013774.1A patent/CN104168888A/zh active Pending
- 2013-03-11 MX MX2014010808A patent/MX354811B/es active IP Right Grant
- 2013-03-11 NO NO13710293A patent/NO2825156T3/no unknown
- 2013-03-15 TW TW102109381A patent/TWI586370B/zh active
-
2014
- 2014-09-09 IL IL234550A patent/IL234550A/en active IP Right Grant
- 2014-10-15 ZA ZA2014/07490A patent/ZA201407490B/en unknown
- 2014-12-11 HK HK14112479.9A patent/HK1198924A1/xx unknown
-
2018
- 2018-01-11 US US15/867,985 patent/US11510988B2/en active Active
- 2018-01-12 AU AU2018200293A patent/AU2018200293B2/en active Active
- 2018-05-29 JP JP2018102256A patent/JP2018141015A/ja active Pending